Corcept Therapeutics Incorporated (CORT) — Analyst outlook / Analyst consensus target is. Based on 25 analyst ratings, the consensus is bullish — 13 Buy, 10 Hold, 2 Sell.
The consensus price target is $68.40 (low: $30.00, high: $100.00), representing an upside of 56.6% from the current price $43.68.
Analysts estimate Earnings Per Share (EPS) of $1.41 and revenue of $0.69B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $1.35 vs est $1.41 (missed -4.1%). 2025: actual $0.95 vs est $0.96 (missed -0.6%). Analyst accuracy: 98%.
CORT Stock — 12-Month Price Forecast
$68.40
▲ +56.59% Upside
Average Price Target
Based on 25 Wall Street analysts offering 12-month price targets for Corcept Therapeutics Incorporated, the average price target is $68.40, with a high forecast of $100.00, and a low forecast of $30.00.
The average price target represents a +56.59% change from the last price of $43.68.
Highest Price Target
$100.00
Average Price Target
$68.40
Lowest Price Target
$30.00
CORT Analyst Ratings
Buy
Based on 25 analysts giving stock ratings to Corcept Therapeutics Incorporated in the past 3 months
EPS Estimates — CORT
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $1.35
vs Est $1.41
▼ 4.3% off
2025
Actual $0.95
vs Est $0.96
▼ 0.6% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — CORT
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.675B
vs Est $0.693B
▼ 2.6% off
2025
Actual $0.761B
vs Est $0.816B
▼ 7.2% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
